INCY Incyte Corporation

117.09
-1.31  -1%
Previous Close 118.40
Open 118.38
Price To book 24.04
Market Cap 24664977003
Shares 210,649,731
Volume 1,437,401
Short Ratio 3.36
Av. Daily Volume 1,320,304

SEC filingsSee all SEC filings

  1. 8-K - Current report 171081131
  2. 424B2 - Prospectus [Rule 424(b)(2)] 171079613
  3. 424B3 - Prospectus [Rule 424(b)(3)] 171074891
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17996730
  5. 8-K - Current report 17994685

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing.
INCB54828 (FIGHT-202)
Cholangiocarcinoma
Phase 2 ongoing.
INCB54828 (FIGHT-203)
8p11 MPNs
Phase 2 ongoing.
INCB54828 (FIGHT-201)
Bladder cancer
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Phase 1/2 enrolling.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Cancer - solid tumors
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Approved November 16, 2011.
Jakafi
Myelofibrosis
Phase 3 initiation of dosing announced July 20, 2017.
Itacitinib - GRAVITAS-301
Treatment-naïve acute GVHD
Phase 3 trial to be initiated in 2018.
Baricitinib
Psoriatic arthritis
Phase 2 commenced February 2017.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal Phase 2 trial open for enrollment - as of August 2017.
Ruxolitinib (RESET-272)
Essential thrombocythemia
Phase 3 trial commenced June 2017.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 enrollment commenced March 2017. Trial to be completed in 2020.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Announced January 19 2016 that NDA Filing had been submitted. Three month delay announced January 13, 2017. CRL received April 14, 2017. Noted August 30, 2017 that NDA will be resubmitted before the end of January 2018.
Baricitinib
Rheumatoid arthritis
Phase 2 initiated October 2015
Ruxolitinib cream
Topical treatment of alopecia areata
Phase 3 initiated June 2016. Initial data due 2018
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 1/2 in combination with osimertinib (EGFR) expected to initiate 4Q 2016.
INCB39110 with osimertinib (EGFR)
Lung cancer
Ongoing
Epacadostat
Cancer - multiple tumor types
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 2 pivotal trial dosing initiation announced December 30, 2016.
Ruxolitinib - REACH 1
Graft versus host disease

Latest News

  1. Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress
  2. Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell
  3. Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
  4. Lilly/Incyte pill beats placebo in mid-stage eczema trial
  5. Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?
  6. Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
  7. ETFs with exposure to Incyte Corp. : September 13, 2017
  8. This Analyst Predicts Bullish Growth Outlook For Incyte
  9. Incyte Corp. :INCY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
  10. Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : September 11, 2017
  11. [$$] AstraZeneca, Merck and Inctye boosted by cancer treatment advances
  12. Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
  13. Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
  14. Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers
  15. Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock
  16. Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock
  17. Alexion: Quite a Comeback
  18. The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
  19. Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda

SEC Filings

  1. 8-K - Current report 171081131
  2. 424B2 - Prospectus [Rule 424(b)(2)] 171079613
  3. 424B3 - Prospectus [Rule 424(b)(3)] 171074891
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17996730
  5. 8-K - Current report 17994685
  6. CT ORDER - Confidential treatment order 17956619
  7. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 17943217
  8. 8-K - Current report 17877444
  9. CT ORDER - Confidential treatment order 17842088
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814284